STTK Profile
Shattuck Labs, Inc., headquartered in Austin, Texas, operates as a dynamic clinical-stage biotechnology firm specializing in the development of innovative therapeutics for cancer and autoimmune diseases. Established in 2016, Shattuck Labs has emerged as a frontrunner in the biopharmaceutical industry, leveraging cutting-edge research and development to address critical unmet medical needs.
At the forefront of its pipeline is SL-172154, the company's lead product candidate currently undergoing Phase 1 clinical trials. SL-172154 is specifically designed for the treatment of ovarian, fallopian tube, and peritoneal cancers, showcasing Shattuck Labs' commitment to advancing novel therapies that target cancerous cells with precision and efficacy. Additionally, the company is advancing SL-279252 through Phase 1 clinical trials, focusing on patients with advanced solid tumors and lymphoma, further underscoring its dedication to therapeutic innovation.
Beyond its clinical programs, Shattuck Labs continues to expand its scientific capabilities and strategic partnerships to accelerate the development and commercialization of groundbreaking treatments. The company's robust research platform integrates advanced technologies and methodologies to identify and advance promising drug candidates, positioning it at the forefront of biotechnological innovation.
With a strong foundation built on scientific excellence and a patient-centric approach, Shattuck Labs remains poised to make significant strides in the fields of oncology and autoimmune diseases. By harnessing the power of its proprietary technologies and fostering collaborative relationships within the scientific community, Shattuck Labs aims to redefine treatment paradigms and improve outcomes for patients worldwide.
|
